GLP-TZ

GLP-TZ

Trusted & appreciated by 5,000+ researchers

£50.00

COA
Buy Now
Stock up & save
£50.00
1 Vial
8% Off
£46.00
2 Vials
15% Off
£43.00
3 Vials
22% Off
£39.00
5 Vials
30% Off
£35.00
Kit (10 Vials)
Research Use Only: These products are intended for laboratory research purposes only. By purchasing, you confirm you are a qualified researcher and understand this product is not for personal use.
Visa
Mastercard
Google Pay
SEPA
iDEAL
Bitcoin
Ethereum
USDT
SKU: TR10 Category: Tags: , , , , , ,

Description

Tirzepatide

GLP-TZ is a synthetic 39-amino acid peptide and the first dual GIP/GLP-1 receptor agonist — sometimes referred to as a “twincretin” — developed to simultaneously activate two hormone pathways involved in blood sugar regulation and energy metabolism (Dahl et al., 2021).

Mechanism of Action

  • GLP-TZ activates both the GIP receptor and the GLP-1 receptor, two key signalling pathways that regulate insulin release, appetite, and fat metabolism
  • Research shows it engages the GIP receptor with greater affinity than the GLP-1 receptor, and demonstrates a distinct signalling profile at the GLP-1 receptor compared to selective GLP-1 agonists — a characteristic described as “imbalanced and biased” agonism (Willard et al., 2020)
  • Through these pathways, it promotes insulin release in response to food, reduces appetite signals in the brain, and slows the rate at which the stomach empties (Nauck & D’Alessio, 2022)

Key Research Findings

  • Across the phase 3 SURPASS clinical trial programme, tirzepatide demonstrated reductions in blood glucose and body weight that exceeded those achieved by selective GLP-1 agonists, including semaglutide (Dahl et al., 2021)
  • In preclinical and early clinical models, the combined GIP and GLP-1 receptor activation showed a synergistic effect on insulin response and metabolic outcomes beyond what either pathway achieves alone (Willard et al., 2020)
  • Emerging research also points to potential applications in metabolic liver disease, cardiovascular risk reduction, and kidney function, reflecting the broad reach of GIP and GLP-1 receptor signalling (Karam et al., 2025)

For research use only. Not intended for use in humans or animals.

References

Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2021). https://pubmed.ncbi.nlm.nih.gov/33325008/

Karam, G., Dib, C., Tannous, M., Farhat, Z., Khaddaj, H., & Mourad, A. (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12507501/

Nauck, M. A., & D’Alessio, D. A. (2022). https://pubmed.ncbi.nlm.nih.gov/36050763/

Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Stutsman, C., Bruemmer, D., Sloop, K. W., & Rosenkilde, M. M. (2020). https://pubmed.ncbi.nlm.nih.gov/32730231/

Additional information

Size

10mg/vial

What are peptides?

Peptides are short chains of amino acids that act as signalling molecules in the body, playing a role in a wide range of biological processes including tissue repair, immune response, and cellular communication.

How are peptides used in research?

In research settings, peptides are studied for their ability to interact with specific receptors and biological pathways. This makes them valuable tools for scientific and laboratory analysis, helping researchers better understand how the body functions at a cellular level.

What payment methods do you accept?

We currently accept Credit Card, SEPA bank transfer, iDeal, Google Pay, Apple Pay, and Cryptocurrency (Bitcoin, Ethereum, and USDT).

How should I store my peptides?

All peptides are supplied in lyophilised (freeze-dried) form, ensuring stability during shipping and long-term storage. Unreconstituted vials should be kept in a cool, dry place away from direct light, with refrigeration recommended for extended periods. Once reconstituted for research purposes, peptides should be kept refrigerated and handled using sterile laboratory practices to maintain integrity throughout use.

How does shipping and delivery work?

Orders are processed and dispatched within 48 hours of purchase. Delivery typically takes 6-9 business days depending on your location. Tracking information is available directly on our website. Free shipping is applied automatically on all orders over 150 euros.

Do you offer refunds or returns?

Due to the nature of research products, we are unable to accept returns. However if your order arrives damaged or incorrect please contact us within 48 hours.

How can I be sure of product quality?

All our products are lab-tested by Janoshik to ensure high purity and compliance with research-grade quality standards.

Tirzepatide

GLP-TZ is a synthetic 39-amino acid peptide and the first dual GIP/GLP-1 receptor agonist — sometimes referred to as a “twincretin” — developed to simultaneously activate two hormone pathways involved in blood sugar regulation and energy metabolism (Dahl et al., 2021).

Mechanism of Action

  • GLP-TZ activates both the GIP receptor and the GLP-1 receptor, two key signalling pathways that regulate insulin release, appetite, and fat metabolism
  • Research shows it engages the GIP receptor with greater affinity than the GLP-1 receptor, and demonstrates a distinct signalling profile at the GLP-1 receptor compared to selective GLP-1 agonists — a characteristic described as “imbalanced and biased” agonism (Willard et al., 2020)
  • Through these pathways, it promotes insulin release in response to food, reduces appetite signals in the brain, and slows the rate at which the stomach empties (Nauck & D’Alessio, 2022)

Key Research Findings

  • Across the phase 3 SURPASS clinical trial programme, tirzepatide demonstrated reductions in blood glucose and body weight that exceeded those achieved by selective GLP-1 agonists, including semaglutide (Dahl et al., 2021)
  • In preclinical and early clinical models, the combined GIP and GLP-1 receptor activation showed a synergistic effect on insulin response and metabolic outcomes beyond what either pathway achieves alone (Willard et al., 2020)
  • Emerging research also points to potential applications in metabolic liver disease, cardiovascular risk reduction, and kidney function, reflecting the broad reach of GIP and GLP-1 receptor signalling (Karam et al., 2025)

For research use only. Not intended for use in humans or animals.

References

Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2021). https://pubmed.ncbi.nlm.nih.gov/33325008/

Karam, G., Dib, C., Tannous, M., Farhat, Z., Khaddaj, H., & Mourad, A. (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12507501/

Nauck, M. A., & D’Alessio, D. A. (2022). https://pubmed.ncbi.nlm.nih.gov/36050763/

Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Stutsman, C., Bruemmer, D., Sloop, K. W., & Rosenkilde, M. M. (2020). https://pubmed.ncbi.nlm.nih.gov/32730231/

Related products